ATHE

Alterity Therapeutics Ltd

$5.58 +0.09 (+1.64%) At close · Jul 8

Market Cap

$101.14M

18,125,694

Press releases and events scraped from the company's investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.

Past events

Date	Event	Type
2026-07-07	Alterity Therapeutics Receives FDA End-of-Phase 2 Meeting Minutes Confirming Registrational Pathway for ATH434 in Multiple System Atrophy	Event
2026-06-09	Alterity Therapeutics Achieves Alignment with U.S. FDA on Pivotal Phase 3 Program for ATH434 in Multiple System Atrophy	Event
2026-05-19	Alterity Therapeutics Data Presentations Support Advancement of ATH434 into Phase 3 in Multiple System Atrophy	Presentation
2026-05-11	Alterity Therapeutics Announces Publication Demonstrating the Utility of Quantitative MRI as a Biomarker for Multiple System Atrophy	Event
2026-05-07	Alterity Therapeutics to Deliver Presentations at Multiple Medical Conferences in May 2026	Conference
2026-04-30	Alterity Therapeutics Releases Appendix 4C – Q3 FY26 Quarterly Cash Flow Report & Corporate Update	Event
2026-04-27	Alterity Therapeutics Receives Positive FDA Feedback Following Second Type C Meeting on ATH434 Phase 3 Program in Multiple System Atrophy	Event
2026-04-22	Alterity Therapeutics Presents New Analysis of ATH434 Phase 2 Trial Data in Late Breaking Science Session of the American Academy of Neurology	Event
2026-04-17	Alterity Therapeutics Appoints Highly Experienced Biotech Executive Ann Cunningham to its Board of Directors	Event
2026-04-16	Alterity Therapeutics Announces Late-Breaker Oral Presentation at the American Academy of Neurology Annual Meeting	Shareholder meeting
2026-04-15	Alterity Therapeutics to Host Virtual KOL Event to Share New Insights on ATH434 for the Treatment of Multiple System Atrophy	Event
2026-03-30	Alterity Therapeutics Receives Positive FDA Feedback Following Type C Meeting on ATH434 Phase 3 Program	Event
2026-03-09	Alterity Therapeutics to Participate in the Bell Potter Healthcare Horizons Summit	Event
2026-03-04	Alterity Therapeutics Appoints Daniel O. Claassen, M.D., M.S., as Chief Medical Advisor	Event
2026-03-02	Alterity Therapeutics Recognizes Multiple System Atrophy (MSA) Awareness Month in March and the Urgent Need for Disease-Modifying Treatments	Event
2026-01-30	Appendix 4C – Q2 FY26 Quarterly Cash Flow Report & Corporate Update	Event
2026-01-21	Alterity Therapeutics Issues Shareholder Letter Highlighting 2025 Progress and Key Objectives for 2026	Shareholder meeting
2025-11-21	Chairman's Address 2025 Annual General Meeting	Event
2025-11-21	AGM 2025 Presentation	Presentation
2025-11-12	Alterity Therapeutics to Present at the Bell Potter Healthcare Virtual Conference	Conference
2025-11-10	Alterity Therapeutics Presents Promising Impact of ATH434 on Orthostatic Hypotension and Disease Progression in MSAat the 36th International Symposium on the Autonomic Nervous System	Event
2025-11-03	Appendix 4C - Q1 FY26 Quarterly Cash Flow Report	Event
2025-10-09	Alterity Therapeutics Presents Positive Data from ATH434 Phase 2 Trial at the 2025 International Congress of Parkinson’s Disease and Movement Disorders	Event
2025-10-02	Alterity Therapeutics to Deliver Multiple Presentations at the 2025 International Congress of Parkinson’s Disease and Movement Disorders	Presentation
2025-09-29	Alterity Therapeutics Reports New Commercial Assessment for ATH434 in Multiple System Atrophy	Event

Source: https://www.alteritytherapeutics.com/investors

Key facts CIK 1131343 CUSIP 02155X205 13F (30d) 2 filings 2 filers Visit website Investor relations